<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875429</url>
  </required_header>
  <id_info>
    <org_study_id>17-07</org_study_id>
    <nct_id>NCT04875429</nct_id>
  </id_info>
  <brief_title>Zenith® Fenestrated+ Clinical Study</brief_title>
  <official_title>Zenith® Fenestrated+ Endovascular Graft Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook Research Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook Group Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and&#xD;
      effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the&#xD;
      BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BGUS) for the treatment of&#xD;
      patients with aortic aneurysms involving one or more of the major visceral arteries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">August 2027</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite measure of device technical success and procedural safety</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Percent of patients with device technical success and freedom from procedural safety events in the following criteria:&#xD;
Device technical success which includes delivery, deployment, and withdrawal of the device without the need for unanticipated corrective intervention), and&#xD;
Freedom from the following procedural safety events: rupture, aneurysm-related mortality, permanent paraplegia, new onset renal failure requiring dialysis, bowel ischemia requiring surgery, and disabling stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite measure of freedom from aneurysm-related mortality and clinically significant reintervention</measure>
    <time_frame>12 months post procedure</time_frame>
    <description>Percent of patients meeting the following criteria:&#xD;
Freedom from aneurysm-related mortality (death from aneurysm rupture, death from any cause occurring within 30 days of procedure or secondary intervention or device or procedure related death) and&#xD;
Freedom from clinically significant reintervention (including open surgery to restore blood flow or restore bodily function, any device related intervention requiring hospitalization, placement of an additional endovascular graft component(s), placement of a stent(s) as indicated for loss of or for having inadequate fixation, seal or patency)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <condition>Juxtarenal Aortic Aneurysm</condition>
  <condition>Extent IV Thoracoabdominal</condition>
  <condition>Pararenal Aneurysm</condition>
  <arm_group>
    <arm_group_label>Aortic abdominal aneurysm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System</intervention_name>
    <description>Endovascular aneurysm repair</description>
    <arm_group_label>Aortic abdominal aneurysm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Include Criteria:&#xD;
&#xD;
          1. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a diameter ≥ 50 mm&#xD;
&#xD;
          2. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a growth rate of ≥ 5 mm&#xD;
             in 6 months&#xD;
&#xD;
          3. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with aortic diameter &gt; 2x&#xD;
             the normal aortic diameter or saccular aneurysm that warrants treatment in the opinion&#xD;
             of the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years&#xD;
&#xD;
          2. Life expectancy &lt; 2 years&#xD;
&#xD;
          3. Pregnant, breast-feeding, or planning to become pregnant within 60 months&#xD;
&#xD;
          4. Inability or refusal to give informed consent by the patient or legally authorized&#xD;
             representative&#xD;
&#xD;
          5. Unwilling or unable to comply with the follow-up schedule, required clinical&#xD;
             assessments, and imaging&#xD;
&#xD;
          6. Simultaneous participation in another investigation study, unless the patient is at&#xD;
             least 30 days beyond the primary endpoint of any previous study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Oderich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Hermann Texas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chanda Bell, RN, BSN</last_name>
    <phone>765-463-7537</phone>
    <phone_ext>321506</phone_ext>
    <email>chanda.bell@cookmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pedro Ribelles</last_name>
    <phone>+33 (0) 660523152</phone>
    <email>pedro.ribelles@cookmedical.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endovascular</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Fenestration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Cook Research Incorporated (CRI) is fully committed to supporting the principles of responsible data sharing, including providing qualified scientific researchers access to deidentified, patient-level data from CRI clinical studies to conduct legitimate scientific research. Data underlying the results reported in this clinical study will be made available for request after publication of the results from this study and ending 5 years after initial publication. Interested researchers may review the &quot;Cook Research Incorporated Policy on Access to Clinical Study Data&quot; at https://www.cookresearchinc.com/extranet/data-access.html and submit a complete research proposal to request data access. Additional study documents (such as the study protocol) will be shared as needed if the data access request is granted. A data sharing agreement will be executed for access to deidentified patient-level data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

